Loading clinical trials...
Loading clinical trials...
The purpose of the study is for investigation and collection of Aricept safety information with a dose increase on Alzheimer's disease patients.
This is an observational study to systematically investigate domestic patients with Alzheimer's disease to figure out the safety under a situation of the use of Donepezil HCl 23mg. Additionally, if the dose of Donepezil HCl increase, there is need to examine the safety of Donepezil HCl 23mg in depth for patients with Alzheimer's disease by comparing aspects of occurring adverse events by the type of Donepezil HCl increase.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Busan, South Korea
Chungcheongbuk-do, South Korea
Chungcheongnam-do, South Korea
Daegu, South Korea
Gangwon-do, South Korea
Gwangju, South Korea
Gyeonggji-do, South Korea
Gyeongsangbuk-do, South Korea
Gyeongsangnam-do, South Korea
Jeju-do, South Korea
Start Date
March 1, 2015
Primary Completion Date
June 1, 2016
Completion Date
June 1, 2016
Last Updated
March 7, 2017
2,231
ACTUAL participants
Aricept
DRUG
Lead Sponsor
Eisai Korea Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07033494